Summary of Inovio's Q2 2026 Earnings Call

1Key Financial Results and Metrics

Net Proceeds: Inovio raised $18.3 million from a public offering in July 2026.

Cash Position: As of June 30, 2026, cash and equivalents stood at $36.7 million, down from $58.5 million at the end of 2025.

Operational Cash Burn: Estimated at $18 million for Q3 2026, with projections indicating sufficient cash to support operations into late Q1 2027.

Net Loss: Reported at $6 million ($0.07 per share), significantly reduced from a net loss of $23.5 million ($0.61 per share) in Q2 2025, primarily due to a $13.9 million noncash gain related to warrant liabilities.

2Strategic Updates and Business Highlights

Regulatory Progress: The FDA's review of the Biologics License Application (BLA) for INO-3.11 thousand is on track for a PDUFA date of October 30, 2026. The FDA has completed key inspections and held an informal meeting to discuss the data supporting INO-3.11 thousand.

Commercial Launch Preparations: Inovio is building its launch infrastructure and has engaged Syneos Health as a contract sales organization to support commercialization efforts.

Pipeline Developments: Positive Phase III results for VGX-3.1 thousand in China for cervical dysplasia were announced, and new rare disease targets were added to the DPROT technology platform.

3Forward Guidance and Outlook

Inovio expects to maintain its cash runway through late Q1 2027, covering prelaunch inventory and marketing expenses.

The company anticipates starting label negotiations in September 2026 and is preparing for a potential launch of INO-3.11 thousand if approved.

4Bad News, Challenges, or Points of Concern

Regulatory Risks: While the FDA has not raised significant concerns, the outcome of the review process remains uncertain, particularly regarding the confirmatory trial design and its implications for approval.

Market Competition: The early uptake of PAPZIMEOS indicates a validated unmet need, but INO-3.11 thousand will face competition from existing treatments, and its market acceptance is not guaranteed.

Cash Management: Although current projections indicate sufficient funds, the company must manage its cash burn carefully to avoid the need for additional capital raises before the anticipated launch.

5Notable Q&A Insights

FDA Meeting Details: The informal meeting with the FDA provided an opportunity to present comprehensive data on INO-3.11 thousand, but no new efficacy or safety questions were raised. The FDA's feedback on the confirmatory trial design is still pending.

Capital Raise Speculation: Management indicated no immediate plans for another capital raise before the PDUFA date, as current funding is expected to support operations through the launch.

Launch Preparations: The financial projections include costs for prelaunch inventory and marketing, indicating a proactive approach to ensure readiness for market entry. Overall, Inovio is positioned for a critical period leading up to the potential launch of INO-3.11 thousand, with a focus on addressing unmet patient needs while navigating regulatory and competitive challenges.